Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept

Fig. 4

Least squares mean (LSM) change from baseline in disease outcomes through 1 year. A CDAI; B SDAI; C DAS28-CRP; D RAPID3; E HAQ-DI. All between-group comparisons were p > 0.05. All within-group differences from baseline over time were p < 0.01. CDAI: Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score 28-C-reactive protein; HAQ-DI: Health Assessment Questionnaire-Disability Index; RAPID3: Routine Assessment of Patient Index Data 3; RC: routine care; SDAI: Simple Disease Activity Index; T2T: treat-to-target

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us